| Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis HA Hill, X Qi, P Jain, K Nomie, Y Wang, S Zhou, ML Wang Blood advances 4 (13), 2927-2938, 2020 | 104 | 2020 |
| Ibrutinib with rituximab in first-line treatment of older patients with mantle cell lymphoma P Jain, S Zhao, HJ Lee, HA Hill, CY Ok, R Kanagal-Shamanna, ... Journal of Clinical Oncology 40 (2), 202-212, 2022 | 78 | 2022 |
| Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL)‐outcomes and mutation profile from venetoclax resistant MCL patients S Zhao, R Kanagal‐Shamanna, L Navsaria, CY Ok, S Zhang, K Nomie, ... American journal of hematology 95 (6), 623-629, 2020 | 77 | 2020 |
| Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL P Jain, S Zhang, R Kanagal-Shamanna, CY Ok, K Nomie, GN Gonzalez, ... Blood Advances 4 (6), 1038-1050, 2020 | 57 | 2020 |
| Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma S Zhang, VC Jiang, G Han, D Hao, J Lian, Y Liu, Q Cai, R Zhang, ... Nature communications 12 (1), 2877, 2021 | 54 | 2021 |
| Ibrutinib–rituximab followed by R-HCVAD as frontline treatment for young patients (≤ 65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial ML Wang, P Jain, S Zhao, HJ Lee, L Nastoupil, L Fayad, CY Ok, ... The Lancet Oncology 23 (3), 406-415, 2022 | 50 | 2022 |
| Ibrutinib plus rituximab and venetoclax (IRV) followed by risk-stratified observation or short course R-hypercvad/MTX in young patients with previously untreated mantle cell … M Wang, P Jain, HJ Lee, CY Ok, H Hill, L Navsaria, R Kanagal-Shamanna, ... Blood 138, 3525, 2021 | 20 | 2021 |
| Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations Y Che, Y Liu, Y Yao, HA Hill, Y Li, Q Cai, F Yan, P Jain, W Wang, L Rui, ... Blood cancer journal 13 (1), 27, 2023 | 17 | 2023 |
| CAR-T and other adoptive cell therapies for B cell malignancies P Lu, HA Hill, LJ Navsaria, ML Wang Journal of the National Cancer Center 1 (3), 88-96, 2021 | 12 | 2021 |
| Acalabrutinib with Rituximab As First-Line Therapy for Older Patients with Mantle Cell Lymphoma-a Phase II Clinical Trial P Jain, CY OK, LJ Nastoupil, J Westin, HA Hill, R Nair, SP Iyer, A Fetooh, ... Blood 142, 3036, 2023 | 10 | 2023 |
| Immune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma P Jain, K Nomie, N Kotlov, VI Segodin, H Hill, CY Ok, A Fetooh, ... Blood cancer journal 13 (1), 156, 2023 | 6 | 2023 |
| Forecasting Acute Kidney Injury and Resource Utilization in ICU patients using longitudinal, multimodal models Y Tan, M Dede, V Mohanty, J Dou, H Hill, E Bernstam, K Chen Journal of Biomedical Informatics 154, 104648, 2024 | 5 | 2024 |
| Combination of ibrutinib with rituximab (IR) in previously untreated older patients with mantle cell lymphoma (MCL)-a phase II clinical trial P Jain, Y Yao, S Zhao, Y Liu, H Hill, Y Che, Y Li, AA Jordan, J McIntosh, ... Blood 136, 41-42, 2020 | 5 | 2020 |
| IBRUTINIB‐RITUXIMAB AND VENETOCLAX (IRV) FOLLOWED BY RISK‐STRATIFIED R‐HYPERCVAD/MTX IN YOUNG PATIENTS WITH UNTREATED MANTLE CELL LYMPHOMA—PHASE‐II WINDOW‐2 TRIAL. ML Wang, HJ Lee, A Fetooh, R Nair, CY Ok, HA Hill, SP Iyer, RE Steiner, ... Hematological Oncology 41, 2023 | 4 | 2023 |
| Ibrutinib plus rituximab (IR) followed by short course R-hypercvad/MTX in Patients (age≤ 65 years) with previously untreated mantle cell lymphoma-Phase-II window-1 clinical trial M Wang, P Jain, Y Yao, Y Liu, S Zhao, H Hill, O Moghrabi, HJ Lee, ... Blood 136, 35-36, 2020 | 4 | 2020 |
| Six Years Follow up of Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hyper CVAD/MTX in Patients (age≤ 65 years) with Previously Untreated Mantle Cell Lymphoma-Phase … P Jain, HJ Lee, J Westin, LJ Nastoupil, L Fayad, R Nair, SP Iyer, ... Blood 142, 1688, 2023 | 3 | 2023 |
| Integrative Prognostic Machine Learning Models in Mantle Cell Lymphoma HA Hill, P Jain, CY Ok, K Sasaki, H Chen, ML Wang, K Chen Cancer Research Communications 3 (8), 1435-1446, 2023 | 2 | 2023 |
| Targeting the Synthetic Lethality Interaction of MTAP and PRMT5 to Overcome Drug Resistance and Enhance Anti-Cancer Immunity in Mantle Cell Lymphoma Yixin Yao, Lingzhi Li, Yuxuan Che, Joseph McIntosh, Holly Hill, Yang Liu ... Blood 136 (Supplement 1), 15, 2020 | 2 | 2020 |
| Non-Bcl2 Mutations Are Predominant in Patients (pts) with Venetoclax Resistant Mantle Cell Lymphoma (MCL)-Response and Clinical Outcomes in Ultra-Refractory MCL P Jain, S Zhao, R Kanagal-Shamanna, L Navsaria, H Hill, A Misra, ... Blood 134, 2815, 2019 | 2 | 2019 |
| Abstract HER2-01: HER2-01 Clinical and Molecular Characteristics of HER2-low/zero Early Stage Triple-Negative Breast Cancer C Yam, Z Li, A Korkut, W Ma, E Kong, HA Hill, H Abbas, S Abouharb, ... Cancer Research 83 (5_Supplement), HER2-01-HER2-01, 2023 | 1 | 2023 |